{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:11:37Z","timestamp":1787962297989,"version":"build-2784847793"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2018,10,10]],"date-time":"2018-10-10T00:00:00Z","timestamp":1539129600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1007\/s00296-018-4161-7","type":"journal-article","created":{"date-parts":[[2018,10,10]],"date-time":"2018-10-10T00:53:06Z","timestamp":1539132786000},"page":"2111-2120","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Patterns of the initiation of disease-modifying antirheumatic drugs in incident rheumatoid arthritis: a German perspective based on nationwide ambulatory drug prescription data"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4072-9245","authenticated-orcid":false,"given":"Annika","family":"Steffen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob","family":"Holstiege","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Klimke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2310-3179","authenticated-orcid":false,"given":"Manas K.","family":"Akmatov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"B\u00e4tzing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,10,10]]},"reference":[{"issue":"10055","key":"4161_CR1","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","volume":"388","author":"JS Smolen","year":"2016","unstructured":"Smolen JS, Aletaha D, McInnes IB (2016) Rheumatoid arthritis. Lancet 388(10055):2023\u20132038. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(16)30173-8","journal-title":"Lancet"},{"issue":"13 Suppl","key":"4161_CR2","first-page":"S295","volume":"18","author":"A Gibofsky","year":"2012","unstructured":"Gibofsky A (2012) Overview of epidemiology, pathophysiology, and diagnosis of rheumatoid arthritis. Am J Manag Care 18(13 Suppl):S295\u2013S302","journal-title":"Am J Manag Care"},{"key":"4161_CR3","unstructured":"Steffen A, Holstiege J, Goffrier B, B\u00e4tzing J (2017) Epidemiology of rheumatoid arthritis in Germany\u2014an analysis based on nationwide claims data of outpatient care. Central Research Institute of Ambulatory Health Care in Germany. \n                    https:\/\/www.versorgungsatlas.de\/fileadmin\/ziva_docs\/85\/VA-85-RheumatoideArthritis-Abstract-English.pdf\n                    \n                  . Accessed 20 Apr 2018"},{"issue":"1","key":"4161_CR4","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jbspin.2012.02.005","volume":"80","author":"S Dadoun","year":"2013","unstructured":"Dadoun S, Zeboulon-Ktorza N, Combescure C, Elhai M, Rozenberg S, Gossec L, Fautrel B (2013) Mortality in rheumatoid arthritis over the last fifty years: systematic review and meta-analysis. Jt Bone Spine 80(1):29\u201333. \n                    https:\/\/doi.org\/10.1016\/j.jbspin.2012.02.005","journal-title":"Jt Bone Spine"},{"issue":"Suppl 6","key":"4161_CR5","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1093\/rheumatology\/kes278","volume":"51","author":"KS Upchurch","year":"2012","unstructured":"Upchurch KS, Kay J (2012) Evolution of treatment for rheumatoid arthritis. Rheumatology (Oxford) 51(Suppl 6):28\u201336. \n                    https:\/\/doi.org\/10.1093\/rheumatology\/kes278","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"4161_CR6","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","volume":"76","author":"JS Smolen","year":"2017","unstructured":"Smolen JS, Landew\u00e9 R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, Nam J, Ramiro S, Voshaar M, van Vollenhoven R, Aletaha D, Aringer M, Boers M, Buckley CD, Buttgereit F, Bykerk V, Cardiel M, Combe B, Cutolo M, van Eijk-Hustings Y, Emery P, Finckh A, Gabay C, Gomez-Reino J, Gossec L, Gottenberg J-E, Hazes JMW, Huizinga T, Jani M, Karateev D, Kouloumas M, Kvien T, Li Z, Mariette X, McInnes I, Mysler E, Nash P, Pavelka K, Po\u00f3r G, Richez C, van Riel P, Rubbert-Roth A, Saag K, da Silva J, Stamm T, Takeuchi T, Westhovens R, de Wit M, van der Heijde D (2017) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 76(6):960\u2013977. \n                    https:\/\/doi.org\/10.1136\/annrheumdis-2016-210715","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"4161_CR7","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1136\/ard.2009.126532","volume":"69","author":"JS Smolen","year":"2010","unstructured":"Smolen JS, Landew\u00e9 R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, Gorter S, Knevel R, Nam J, Schoels M, Aletaha D, Buch M, Gossec L, Huizinga T, Bijlsma JWJW, Burmester G, Combe B, Cutolo M, Gabay C, Gomez-Reino J, Kouloumas M, Kvien TK, Martin-Mola E, McInnes I, Pavelka K, van Riel P, Scholte M, Scott DL, Sokka T, Valesini G, van Vollenhoven R, Winthrop KL, Wong J, Zink A, van der Heijde D (2010) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 69(6):964\u2013975. \n                    https:\/\/doi.org\/10.1136\/ard.2009.126532","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"4161_CR8","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1002\/art.23721","volume":"59","author":"KG Saag","year":"2008","unstructured":"Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, Paulus HE, Mudano A, Pisu M, Elkins-Melton M, Outman R, Allison JJ, Suarez Almazor M, Bridges SL, Chatham WW, Hochberg M, MacLean C, Mikuls T, Moreland LW, O\u2019Dell J, Turkiewicz AM, Furst DE, American College of R (2008) American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 59(6):762\u2013784. \n                    https:\/\/doi.org\/10.1002\/art.23721","journal-title":"Arthritis Rheum"},{"issue":"5","key":"4161_CR9","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1002\/acr.21641","volume":"64","author":"JA Singh","year":"2012","unstructured":"Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, Moreland LW, O\u2019Dell J, Winthrop KL, Beukelman T, Bridges SL, Chatham WW, Paulus HE, Suarez-Almazor M, Bombardier C, Dougados M, Khanna D, King CM, Leong AL, Matteson EL, Schousboe JT, Moynihan E, Kolba KS, Jain A, Volkmann ER, Agrawal H, Bae S, Mudano AS, Patkar NM, Saag KG (2012) 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 64(5):625\u2013639. \n                    https:\/\/doi.org\/10.1002\/acr.21641","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"4161_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/acr.22783","volume":"68","author":"JA Singh","year":"2016","unstructured":"Singh JA, Saag KG, Bridges SL, Akl EA, Bannuru RR, Sullivan MC, Vaysbrot E, McNaughton C, Osani M, Shmerling RH, Curtis JR, Furst DE, Parks D, Kavanaugh A, O\u2019Dell J, King C, Leong A, Matteson EL, Schousboe JT, Drevlow B, Ginsberg S, Grober J, St Clair EW, Tindall E, Miller AS, McAlindon T, American College of R (2016) 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 68(1):1\u201325. \n                    https:\/\/doi.org\/10.1002\/acr.22783","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"4161_CR11","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s00393-012-1093-6","volume":"72","author":"J Wollenhaupt","year":"2013","unstructured":"Wollenhaupt J, Albrecht K, Kr\u00fcger K, M\u00fcller-Ladner U (2013) The new 2012 German recommendations for treating rheumatoid arthritis: differences compared to the European standpoint. Z Rheumatol 72(1):6\u20139. \n                    https:\/\/doi.org\/10.1007\/s00393-012-1093-6","journal-title":"Z Rheumatol"},{"issue":"1","key":"4161_CR12","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1002\/acr.20304","volume":"63","author":"J Widdifield","year":"2011","unstructured":"Widdifield J, Bernatsky S, Paterson JM, Thorne JC, Cividino A, Pope J, Gunraj N, Bombardier C (2011) Quality care in seniors with new-onset rheumatoid arthritis: a Canadian perspective. Arthritis Care Res (Hoboken) 63(1):53\u201357. \n                    https:\/\/doi.org\/10.1002\/acr.20304","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"2","key":"4161_CR13","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.clinthera.2011.12.016","volume":"34","author":"MMK Bonafede","year":"2012","unstructured":"Bonafede MMK, Fox KM, Johnson BH, Watson C, Gandra SR (2012) Factors associated with the initiation of disease-modifying antirheumatic drugs in newly diagnosed rheumatoid arthritis: a retrospective claims database study. Clin Ther 34(2):457\u2013467. \n                    https:\/\/doi.org\/10.1016\/j.clinthera.2011.12.016","journal-title":"Clin Ther"},{"issue":"6","key":"4161_CR14","doi-asserted-by":"publisher","first-page":"e001603","DOI":"10.1136\/bmjopen-2012-001603","volume":"2","author":"CJ Edwards","year":"2012","unstructured":"Edwards CJ, Campbell J, van Staa T, Arden NK (2012) Regional and temporal variation in the treatment of rheumatoid arthritis across the UK: a descriptive register-based cohort study. BMJ Open 2(6):e001603. \n                    https:\/\/doi.org\/10.1136\/bmjopen-2012-001603","journal-title":"BMJ Open"},{"issue":"1","key":"4161_CR15","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s00393-016-0156-5","volume":"76","author":"K Albrecht","year":"2017","unstructured":"Albrecht K, Huscher D, Eidner T, Kleinert S, Sp\u00e4thling-Mestekemper S, Bischoff S, Zink A (2017) Medical treatment of rheumatoid arthritis in 2014: current data from the German Collaborative Arthritis Centers. Z Rheumatol 76(1):50\u201357. \n                    https:\/\/doi.org\/10.1007\/s00393-016-0156-5","journal-title":"Z Rheumatol"},{"issue":"2","key":"4161_CR16","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1007\/s00393-017-0294-4","volume":"77","author":"K Albrecht","year":"2018","unstructured":"Albrecht K, Luque Ramos A, Callhoff J, Hoffmann F, Minden K, Zink A (2018) Outpatient care and disease burden of rheumatoid arthritis: results of a linkage of claims data and a survey of insured persons. Z Rheumatol 77(2):102\u2013112. \n                    https:\/\/doi.org\/10.1007\/s00393-017-0294-4","journal-title":"Z Rheumatol"},{"issue":"4","key":"4161_CR17","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1002\/art.38323","volume":"66","author":"DH Solomon","year":"2014","unstructured":"Solomon DH, Bitton A, Katz JN, Radner H, Brown EM, Fraenkel L (2014) Review: treat to target in rheumatoid arthritis: fact, fiction, or hypothesis? Arthritis Rheumatol 66(4):775\u2013782. \n                    https:\/\/doi.org\/10.1002\/art.38323","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"4161_CR18","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1136\/annrheumdis-2015-207526","volume":"75","author":"MA Stoffer","year":"2016","unstructured":"Stoffer MA, Schoels MM, Smolen JS, Aletaha D, Breedveld FC, Burmester G, Bykerk V, Dougados M, Emery P, Haraoui B, Gomez-Reino J, Kvien TK, Nash P, Navarro-Comp\u00e1n V, Scholte-Voshaar M, van Vollenhoven R, van der Heijde D, Stamm TA (2016) Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update. Ann Rheum Dis 75(1):16\u201322. \n                    https:\/\/doi.org\/10.1136\/annrheumdis-2015-207526","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"4161_CR19","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1136\/ard.2009.123919","volume":"69","author":"JS Smolen","year":"2010","unstructured":"Smolen JS, Aletaha D, Bijlsma JWJ, Breedveld FC, Boumpas D, Burmester G, Combe B, Cutolo M, de Wit M, Dougados M, Emery P, Gibofsky A, Gomez-Reino JJ, Haraoui B, Kalden J, Keystone EC, Kvien TK, McInnes I, Martin-Mola E, Montecucco C, Schoels M, van der Heijde D, van der Heijde D, Committee TTE (2010) Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 69(4):631\u2013637. \n                    https:\/\/doi.org\/10.1136\/ard.2009.123919","journal-title":"Ann Rheum Dis"},{"key":"4161_CR20","unstructured":"Deutsche Gesellschaft f\u00fcr Rheumatologie (2012) S1-Leitlinie der Deutschen Gesellschaft f\u00fcr Rheumatologie: Handlungsempfehlungen der DGRh zur sequenziellen medikament\u00f6sen Therapie der rheumatoiden Arthritis 2012: adaptierte EULAR Empfehlungen und aktualisierter Therapiealgorithmus. \n                    https:\/\/dgrh.de\/dam\/jcr:f887ba34-f7fc-4a6f-bf55-dde42aacb25c\/leitlinie_s1_medikamentoese_therapie_ra.pdf\n                    \n                  . Accessed 20 Apr 2018"},{"issue":"1","key":"4161_CR21","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1002\/art.10727","volume":"48","author":"MaS Bukhari","year":"2003","unstructured":"Bukhari MaS, Wiles NJ, Lunt M, Harrison BJ, Scott DGI, Symmons DPM, Silman AJ (2003) Influence of disease-modifying therapy on radiographic outcome in inflammatory polyarthritis at five years: results from a large observational inception study. Arthritis Rheum 48(1):46\u201353. \n                    https:\/\/doi.org\/10.1002\/art.10727","journal-title":"Arthritis Rheum"},{"issue":"2","key":"4161_CR22","first-page":"84","volume":"9","author":"AM Louder","year":"2016","unstructured":"Louder AM, Singh A, Saverno K, Cappelleri JC, Aten AJ, Koenig AS, Pasquale MK (2016) Patient preferences regarding rheumatoid arthritis therapies: a conjoint analysis. Am Health Drug Benefits 9(2):84\u201393","journal-title":"Am Health Drug Benefits"},{"issue":"1","key":"4161_CR23","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1136\/annrheumdis-2012-202603","volume":"73","author":"P Putrik","year":"2014","unstructured":"Putrik P, Ramiro S, Kvien TK, Sokka T, Pavlova M, Uhlig T, Boonen A, Working Group \u2018Equity in access to treatment of rheumatoid arthritis in E (2014) Inequities in access to biologic and synthetic DMARDs across 46 European countries. Ann Rheum Dis 73 (1):198\u2013206. \n                    https:\/\/doi.org\/10.1136\/annrheumdis-2012-202603","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"4161_CR24","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1001\/jama.2011.67","volume":"305","author":"G Schmajuk","year":"2011","unstructured":"Schmajuk G, Trivedi AN, Solomon DH, Yelin E, Trupin L, Chakravarty EF, Yazdany J (2011) Receipt of disease-modifying antirheumatic drugs among patients with rheumatoid arthritis in Medicare managed care plans. JAMA 305(5):480\u2013486. \n                    https:\/\/doi.org\/10.1001\/jama.2011.67","journal-title":"JAMA"},{"issue":"5","key":"4161_CR25","doi-asserted-by":"publisher","first-page":"401","DOI":"10.18553\/jmcp.2015.21.5.401","volume":"21","author":"G Kim","year":"2015","unstructured":"Kim G, Barner JC, Rascati K, Richards K (2015) Factors associated with the initiation of biologic disease-modifying antirheumatic drugs in Texas Medicaid patients with rheumatoid arthritis. J Manag Care Spec Pharm 21(5):401\u2013407. \n                    https:\/\/doi.org\/10.18553\/jmcp.2015.21.5.401","journal-title":"J Manag Care Spec Pharm"},{"issue":"2","key":"4161_CR26","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1002\/art.21077","volume":"53","author":"D Lacaille","year":"2005","unstructured":"Lacaille D, Anis AH, Guh DP, Esdaile JM (2005) Gaps in care for rheumatoid arthritis: a population study. Arthritis Rheum 53(2):241\u2013248. \n                    https:\/\/doi.org\/10.1002\/art.21077","journal-title":"Arthritis Rheum"},{"issue":"9","key":"4161_CR27","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1136\/ard.2005.051144","volume":"65","author":"Z Tutuncu","year":"2006","unstructured":"Tutuncu Z, Reed G, Kremer J, Kavanaugh A (2006) Do patients with older-onset rheumatoid arthritis receive less aggressive treatment? Ann Rheum Dis 65(9):1226\u20131229. \n                    https:\/\/doi.org\/10.1136\/ard.2005.051144","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"4161_CR28","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1136\/annrheumdis-2013-204311","volume":"74","author":"D Huscher","year":"2015","unstructured":"Huscher D, Mittendorf T, von Hin\u00fcber U, K\u00f6tter I, Hoese G, Pf\u00e4fflin A, Bischoff S, Zink A, German Collaborative Arthritis C (2015) Evolution of cost structures in rheumatoid arthritis over the past decade. Ann Rheum Dis 74(4):738\u2013745. \n                    https:\/\/doi.org\/10.1136\/annrheumdis-2013-204311","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"4161_CR29","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.18553\/jmcp.2014.20.11.1110","volume":"20","author":"RJ Desai","year":"2014","unstructured":"Desai RJ, Rao JK, Hansen RA, Fang G, Maciejewski ML, Farley JF (2014) Predictors of treatment initiation with tumor necrosis factor-\u03b1 inhibitors in patients with rheumatoid arthritis. J Manag Care Spec Pharm 20(11):1110\u20131120. \n                    https:\/\/doi.org\/10.18553\/jmcp.2014.20.11.1110","journal-title":"J Manag Care Spec Pharm"},{"issue":"7","key":"4161_CR30","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1093\/rheumatology\/kew048","volume":"55","author":"P Putrik","year":"2016","unstructured":"Putrik P, Ramiro S, Lie E, Keszei AP, Kvien TK, van der Heijde D, Landewe R, Uhlig T, Boonen A (2016) Less educated and older patients have reduced access to biologic DMARDs even in a country with highly developed social welfare (Norway): results from Norwegian cohort study NOR-DMARD. Rheumatology 55(7):1217\u20131224. \n                    https:\/\/doi.org\/10.1093\/rheumatology\/kew048","journal-title":"Rheumatology"},{"issue":"12","key":"4161_CR31","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1093\/rheumatology\/kel144","volume":"45","author":"L Fraenkel","year":"2006","unstructured":"Fraenkel L, Rabidou N, Dhar R (2006) Are rheumatologists\u2019 treatment decisions influenced by patients\u2019 age? Rheumatology 45(12):1555\u20131557. \n                    https:\/\/doi.org\/10.1093\/rheumatology\/kel144","journal-title":"Rheumatology"},{"issue":"1","key":"4161_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/msc.110","volume":"6","author":"F Chilton","year":"2008","unstructured":"Chilton F, Collett RA (2008) Treatment choices, preferences and decision-making by patients with rheumatoid arthritis. Musculoskeletal Care 6(1):1\u201314. \n                    https:\/\/doi.org\/10.1002\/msc.110","journal-title":"Musculoskeletal Care"},{"issue":"6","key":"4161_CR33","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1093\/rheumatology\/ket449","volume":"53","author":"MB Arnold","year":"2014","unstructured":"Arnold MB, Bykerk VP, Boire G, Haraoui BP, Hitchon C, Thorne C, Keystone EC, Pope JE, Investigators C (2014) Are there differences between young- and older-onset early inflammatory arthritis and do these impact outcomes? An analysis from the CATCH cohort. Rheumatology 53(6):1075\u20131086. \n                    https:\/\/doi.org\/10.1093\/rheumatology\/ket449","journal-title":"Rheumatology"},{"issue":"2","key":"4161_CR34","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1002\/acr.20674","volume":"64","author":"DH Solomon","year":"2012","unstructured":"Solomon DH, Ayanian JZ, Yelin E, Shaykevich T, Brookhart MA, Katz JN (2012) Use of disease-modifying medications for rheumatoid arthritis by race and ethnicity in the National Ambulatory Medical Care Survey. Arthritis Care Res (Hoboken) 64(2):184\u2013189. \n                    https:\/\/doi.org\/10.1002\/acr.20674","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"73","key":"4161_CR35","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s00393-013-1258-y","volume":"2","author":"A Zink","year":"2014","unstructured":"Zink A (2014) Versorgungsforschung in der Rheumatologie\u2014Aktueller Stand. Z Rheumatol 2(73):115\u2013122. \n                    https:\/\/doi.org\/10.1007\/s00393-013-1258-y","journal-title":"Z Rheumatol"},{"issue":"6","key":"4161_CR36","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1093\/rheumatology\/kep045","volume":"48","author":"G Westhoff","year":"2009","unstructured":"Westhoff G, Schneider M, Raspe H, Zeidler H, Runge C, Volmer T, Zink A (2009) Advance and unmet need of health care for patients with rheumatoid arthritis in the German population\u2014results from the German Rheumatoid Arthritis Population Survey (GRAPS). Rheumatology 48(6):650\u2013657. \n                    https:\/\/doi.org\/10.1093\/rheumatology\/kep045","journal-title":"Rheumatology"},{"issue":"3","key":"4161_CR37","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s00393-017-0297-1","volume":"76","author":"A Zink","year":"2017","unstructured":"Zink A, Braun J, Gromnica-Ihle E, Krause D, Lakomek HJ, Mau W, M\u00fcller-Ladner U, Rautenstrauch J, Specker C, Schneider M (2017) Memorandum of the German Society for Rheumatology on the quality of treatment in rheumatology\u2014update 2016. Z Rheumatol 76(3):195\u2013207. \n                    https:\/\/doi.org\/10.1007\/s00393-017-0297-1","journal-title":"Z Rheumatol"},{"issue":"5","key":"4161_CR38","doi-asserted-by":"publisher","first-page":"934","DOI":"10.3899\/jrheum.080762","volume":"36","author":"M Benhamou","year":"2009","unstructured":"Benhamou M, Rincheval N, Roy C, Foltz V, Rozenberg S, Sibilia J, Schaeverbeke T, Bourgeois P, Ravaud P, Fautrel B (2009) The gap between practice and guidelines in the choice of first-line disease modifying antirheumatic drug in early rheumatoid arthritis: results from the ESPOIR cohort. J Rheumatol 36(5):934\u2013942. \n                    https:\/\/doi.org\/10.3899\/jrheum.080762","journal-title":"J Rheumatol"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00296-018-4161-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-018-4161-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-018-4161-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,9]],"date-time":"2019-10-09T19:25:49Z","timestamp":1570649149000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00296-018-4161-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,10]]},"references-count":38,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["4161"],"URL":"https:\/\/doi.org\/10.1007\/s00296-018-4161-7","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"value":"0172-8172","type":"print"},{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,10]]},"assertion":[{"value":"23 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"AS declares that she has no conflict of interest. JH declares that he has no conflict of interest. KK declares that she has no conflict of interest. MKA declares that he has no conflict of interest. JB declares that he has no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants performed by any of the authors. This study was exempted from institutional review board oversight and informed consent since only anonymized data were analysed in accordance with \u00a7\u00a0300 paragraph 2 Volume V of the Social Security Code (Sozialgesetzbuch (SGB) V).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}